Stem cells from a malignant rat prostate cell line generate prostate cancers in vivo : a model for prostate cancer stem cell propagated tumor growth.

Autor:	Hu WY; Department of Urology, University of Illinois at Chicago Chicago, IL 60612, USA., Liu LF; Department of Urology, University of Illinois at Chicago Chicago, IL 60612, USA., Afradiasbagharani P; Department of Urology, University of Illinois at Chicago Chicago, IL 60612, USA., Lu RL; Department of Urology, University of Illinois at Chicago Chicago, IL 60612, USA., Chen ZL; Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center Boston, MA 02215, USA., Hu DP; Department of Urology, University of Illinois at Chicago Chicago, IL 60612, USA., Birch LA; Department of Urology, University of Illinois at Chicago Chicago, IL 60612, USA., Prins GS; Department of Urology, University of Illinois at Chicago Chicago, IL 60612, USA.
Jazyk:	angličtina
Zdroj:	American journal of clinical and experimental urology [Am J Clin Exp Urol] 2022 Dec 25; Vol. 10 (6), pp. 377-389. Date of Electronic Publication: 2022 Dec 25 (Print Publication: 2022).
Abstrakt:	Cancer stem cells (CSCs) are resistant to conventional cancer therapies, permitting the repopulation of new tumor growth and driving disease progression. Models for testing prostate CSC-propagated tumor growth are presently limited yet necessary for therapeutic advancement. Utilizing the congenic nontumorigenic NRP152 and tumorigenic NRP154 rat prostate epithelial cell lines, the present study investigated the self-renewal, differentiation, and regenerative abilities of prostate stem/progenitor cells and developed a CSC-based PCa model. NRP154 cells expressed reduced levels of tumor suppressor caveolin-1 and increased p-Src as compared to NRP152 cells. Gene knockdown of caveolin-1 in NRP152 cells upregulated p-Src, implicating their role as potential oncogenic mediators in NRP154 cells. A FACS-based Hoechst exclusion assay revealed a side population of stem-like cells (0.1%) in both NRP152 and NRP154 cell lines. Using a 3D Matrigel culture system, stem cells from both cell lines established prostaspheres at a 0.1% efficiency through asymmetric self-renewal and rapid proliferation of daughter progenitor cells. Spheres derived from both cell lines contained CD117 + and CD133 + stem cell subpopulations and basal progenitor cell subpopulations (p63 + and CK5 + ) but were negative for luminal cell CK8 markers at day 7. While some NRP152 sphere cells were androgen receptor (AR) positive at this timepoint, NRP154 cells were AR - up to 30 days of 3D culture. The regenerative capacity of the stem/progenitor cells was demonstrated by in vivo tissue recombination with urogenital sinus mesenchyme (UGM) and renal grafting in nude mice. While stem/progenitor cells from NRP152 spheroids generated normal prostate structures, CSCs and progeny cells from NRP154 tumoroids generated tumor tissues that were characterized by immunohistochemistry. Atypical hyperplasia and prostatic intraepithelial neoplasia (PIN) lesions progressed to adenocarcinoma with kidney invasion over 4 months. This provides clear evidence that prostate CSCs can repopulate new tumor growth outside the prostate gland that rapidly progresses to poorly differentiated adenocarcinoma with invasive capabilities. The dual in vitro / in vivo CSC model system presented herein provides a novel platform for screening therapeutic agents that target prostate CSCs for effective combined treatment protocols for local and advanced disease stages. Competing Interests: None. (AJCEU Copyright © 2022.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu